Who Generates Higher Gross Profit? Incyte Corporation or Perrigo Company plc

A Tale of Two Companies: Incyte Corporation vs. Perrigo Company plc

In the competitive landscape of the pharmaceutical industry, understanding who leads in generating gross profit can offer valuable insights. From 2014 to 2023, Incyte Corporation has shown a remarkable upward trajectory in gross profit, growing by over 576% from 2014 to 2023. In contrast, Perrigo Company plc, while maintaining a steady performance, saw a more modest increase of about 16% over the same period.

Incyte's gross profit surged from approximately $508 million in 2014 to a staggering $3.44 billion in 2023, reflecting its strategic growth and market expansion. Meanwhile, Perrigo's gross profit peaked in 2016 at around $2.05 billion but has since stabilized, ending 2023 with $1.68 billion.

This comparison highlights Incyte's aggressive growth strategy, positioning it as a formidable player in the industry, while Perrigo maintains a steady, albeit slower, growth pace.